Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic

Submitted: 7 September 2022
Accepted: 16 December 2022
Published: 5 June 2023
Abstract Views: 506
PDF: 34
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Background. Large-scale population-based seroprevalence studies of SARS-CoV-2 are essential to characterize the cumulative incidence of SARS-CoV-2 infection and to extrapolate the prevalence of presumptive immunity at the population level. Objective. The objective of our survey was to estimate the cumulative population immunity for COVID-19 and to identify individual characteristics associated with positive serostatus. Materials and Methods. This was a clustered cross-sectional study conducted from July 12 to August 20, 2021, in households in the city of Bangui, the capital of the Central African Republic. Information regarding demographic characteristics (age, gender, and place of residence), and comorbidities (chronic diseases) was collected. A venous blood sample was obtained from each participant to determine the level of total anti-SARS-CoV-2 antibodies using a WANTAI SARS-CoV-2 Ab ELISA kit. Results. All up, 799 participants were surveyed. The average age was 27 years, and 45.8% of the respondents were male (sex ratio: 0.8). The overall proportion of respondents with positive serostatus was 74.1%. Participants over 20 years of age were twice as likely to have positive serostatus, with an OR of 2.2 [95% CI: (1.6, 3.1)]. Conclusions. The results of this survey revealed a high cumulative level of immunity in Bangui, thus indicating a significant degree of spread of SARS-CoV-2 in the population. The public health implications of this immunity to SARS-CoV-2 such as the post-vaccination total antibody kinetics remain to be determined.

WHO. WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV): . Accessed on 20 February 2020 at https://wwwwhoint/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov). 2020.

Kadi N, Khelfaoui M. Population density, a factor in the spread of COVID-19 in Algeria: statistic study. Bull Natl Res Cent. 2020;44(1):138. DOI:

Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med. 2020;9(4). DOI:

Patel EU, Bloch EM, Tobian AAR. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serosurveillance in Blood Donor Populations. J Infect Dis. 2021. DOI:

Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(3):331-40. DOI:

Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314-22. DOI:

Chisale MRO, Ramazanu S, Mwale SE, Kumwenda P, Chipeta M, Kaminga AC, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis. Rev Med Virol. 2021:e2271. DOI:

Ministère de la Santé et de la Population. Rapport de situation journalière de COVID-19 en République centrafricaine. SitRep n° 430 Date : 30 Juin 2021

Bennett S, Woods T, Iiyanage WM, Smith DL. A simplified general method for cluster-sample surveys of health in developing countries. World Health Organization, Geneva, Switzeland. Accessed at April 2021 at WHSQ_1991_44(3)_98-106_eng.pdf;jsessionid=B6D8D7E4368CB6D0164F6BCB58F6E157 (

Wantai SARS-CoV-2 Ab ELISA Diagnostic kit fot total Antibody to SARS-CoV-2 (ELISA) REF WS-1096, Manufacturer’s instructions. Accessed on 12 January, 2021.

Nkuba AN, Makiala SM, Guichet E, Tshiminyi PM, Bazitama YM, Yambayamba MK, et al. High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey. Clin Infect Dis. 2021. DOI:

Batchi-Bouyou AL, Lobaloba Ingoba L, Ndounga M, Vouvoungui JC, Mfoutou Mapanguy CC, Boumpoutou KR, et al. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo. Int J Infect Dis. 2021;106:3-7. DOI:

Fai KN, Corine TM, Bebell LM, Mboringong AB, Nguimbis E, Nsaibirni R, et al. Serologic response to SARS-CoV-2 in an African population. Sci Afr. 2021;12:e00802. DOI:

Nwosu K, Fokam J, Wanda F, Mama L, Orel E, Ray N, et al. SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. Nat Commun. 2021;12(1):5851. DOI:

Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. Nat Commun. 2021;12(1):3966. DOI:

Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021;371(6524):79-82. DOI:

Halatoko WA, Konu YR, Gbeasor-Komlanvi FA, Sadio AJ, Tchankoni MK, Komlanvi KS, et al. Prevalence of SARS-CoV-2 among high-risk populations in Lome (Togo) in 2020. PLoS One. 2020;15(11):e0242124. DOI:

Schoenhals M, Rabenindrina N, Rakotondramanga JM, Dussart P, Randremanana R, Heraud JM, et al. SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic. EBioMedicine. 2021;68:103419. DOI:

Milleliri JM, Coulibaly D, Nyobe B, Rey JL, Lamontagne F, Hocqueloux L, et al. SARS-CoV-2 Infection in Ivory Coast: A Serosurveillance Survey among Gold Mine Workers. Am J Trop Med Hyg. 2021. DOI:

Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SSH, Rezvani SM, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis. 2021;27(2):636-8. DOI:

Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-9. DOI:

Dimeglio C, Herin F, Da-Silva I, Porcheron M, GM. B, Chapuy-Regaud S, et al. Post-vaccination SARS-CoV-2 antibody kinetics and protection duration. J Infect 2021;S0163-4453(21):00483-7, doi: 10.1016/j.jinf.2021.09.013. DOI:

A preprint has previously been published as: "Manirakiza A, Malaka C, Yambiyo BM, Marie-Astrid Vernet, Vernet G, Nakoune E. Very high relative seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic", at"


We have no statement to declare about the access rights over this submission
Manirakiza, A., Malaka , C., Longo, J. de D., Yambiyo , B. M., Diemer , S.-C. H., Namseneï , J., Coti-Reckoundji, C. S. G., Bouhouda, M., Darnycka Belizaire, M. R., Roungou, J. B., Komas , N. P., Grésenguet, G., Vernet, G., Vernet, M.-A., & Nakoune, E. (2023). Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic. Journal of Public Health in Africa, 14(8).


Download data is not yet available.